Form 8-K

8-K — Stereotaxis, Inc.

Accession: 0001493152-26-022488

Filed: 2026-05-12

Period: 2026-05-12

CIK: 0001289340

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001289340

2026-05-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(D) of the Securities Exchange Act Of 1934

Date

of report (Date of earliest event reported): May 12, 2026

STEREOTAXIS,

INC.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

(State

or Other Jurisdiction of Incorporation)

001-36159

94-3120386

(Commission

File Number)

(IRS

Employer Identification No.)

710

North Tucker Boulevard, Suite 110, St. Louis, Missouri

63101

(Address

of Principal Executive Offices)

(Zip

Code)

(314)

678-6100

(Registrant’s

Telephone Number, Including Area Code)

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act: ☐

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

STXS

NYSE

American LLC

Item

2.02

Results

of Operations and Financial Condition

May 12, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting

forth its financial results for the 2026 first quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and

the statements contained therein are incorporated by reference herein.

Forward-Looking

Statements and Additional Information

Statements

are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission

(the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities,

events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements.

These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties

and other important factors that could cause events or the Company’s actual performance or achievements to be materially different

than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read

its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements,

whether as a result of new information, future events or otherwise.

accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not

be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities

Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item

9.01

Financial

Statements and Exhibits

(d)

Exhibits.

99.1

Stereotaxis,

Inc. Earnings Press Release dated May 12, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

STEREOTAXIS,

INC.

Date:

May 12, 2026

By:

/s/

Kimberly R. Peery

Name:

Kimberly

R. Peery

Title:

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Stereotaxis

Reports 2026 First Quarter Financial Results & Business Updates

● Proprietary

robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being

utilized at multiple sites across the United States as well as Europe

● Synchrony

digital operating room system received U.S. FDA clearance in April and initial orders and

shipments are ongoing

● Definitive

agreement to acquire Robocath creates a leading robotic platform, combining complementary

technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum

of endovascular procedures

St.

Louis, MO, May 12, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally

invasive endovascular intervention, today reported business updates and financial results for the first quarter ended March 31, 2026.

“Stereotaxis

is in one of the most exciting periods of its history. We are achieving significant regulatory approvals, executing strategic acquisitions,

and witnessing the initial green shoots of commercial success with our new product ecosystem,” said David Fischel, Stereotaxis

Chairman and CEO. “The operational and commercial friction to ramp up manufacturing and implement new products makes progress gradual,

but we are efficiently driving broad-based progress on many fronts in parallel towards an attractive business built on solid foundations.”

“The

streak of regulatory success that began last year continued in the first part of this year with two essential FDA approvals for the MAGiC

cardiac ablation catheter and Synchrony digital surgery system. These regulatory approvals brought to market an entirely new foundational

product ecosystem that structurally changes our commercial opportunity. We essentially developed a fresh start-up company on the shoulders

of our legacy technology and funded by our legacy business.”

“The

transformational agreement to acquire Robocath gives Stereotaxis a fully complementary and separate robotic mechanism of action for endovascular

device navigation. The combination of our technologies offers a clear vision for how our robotic solution, including the full ecosystem

of digital innovations, will enable remote, automated and fully robotic treatment for electrophysiology, interventional cardiology and

neurointerventions.”

“The

still minor revenue contribution from our new catheters is being countered by the headwind of winding down our relationship with Johnson

& Johnson. Demand for MAGiC far exceeds supply, and we are rolling out the catheter in both Europe and the US in line with the manufacturing

ramp, which continues to progress towards an expected 500 catheters a month by year end. Initial green shoots of adoption demonstrate

the strength of our strategy to build a synergistic portfolio of catheters, with disposable revenue per procedure several fold higher

than previously. This structural transformation to our disposable business model is taking place as we simultaneously structurally transform

our capital business and prepare for multiple GenesisX placements.”

2026

First Quarter Financial Results

Revenue

for the first quarter of 2026 totaled $6.3 million compared to $7.5 million in the prior year first quarter. System revenue of $1.3 million

and recurring revenue of $5.0 million compared to $2.0 million and $5.5 million respectively, in the prior year first quarter. System

revenue in the quarter reflects partial revenue recognition on the installation of one Genesis system and other ancillary systems. Recurring

revenue is pressured by the transition away from the dependency on legacy J&J catheters with still modest contributions from Stereotaxis’

new proprietary catheters.

Gross

margin for the first quarter of 2026 was 60% of revenue. Recurring revenue gross margin was 66%, and system gross margin was 39%. Operating

expenses in the quarter of $9.8 million included $3.1 million in non-cash charges for stock compensation expense, mark-to-market adjustment

for acquisition related contingent earnout consideration, and amortization of acquired intangible assets. Excluding these non-cash charges,

adjusted operating expenses were $6.7 million, compared to the prior year adjusted operating expenses of $6.8 million.

Operating

loss and net loss in the first quarter of 2026 were ($6.0) million and ($5.9) million, respectively, compared with ($5.9) million and

($5.8) million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash charges, were

($2.9) million and ($2.8) million, respectively, compared with ($2.7) million and ($2.6) million in the previous year quarter. Negative

free cash flow for the first quarter was ($3.5) million, compared to ($1.8) million in the previous year.

Cash

Balance and Liquidity

March 31, 2026, Stereotaxis had cash and cash equivalents of $14.6 million and no debt.

Forward

Looking Expectations

Stereotaxis

anticipates double digit revenue growth for the full year 2026, with annual revenue expected to surpass $40 million. Revenue will grow

sequentially over the course of the year in line with manufacturing increases for GenesisX and MAGiC, with revenue in both the third

and fourth quarters expected to exceed $10 million.

Stereotaxis

believes it can advance its strategy, integrate Robocath, and grow significantly without having to subject investors to substantial dilution.

The Company expects its balance sheet to allow it to advance its transformative product ecosystem to market, fund its commercialization,

and achieve profitability.

Conference

Call and Webcast

Stereotaxis

will host a conference call and webcast today, May 12, 2026, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871

(US and Canada) or 646-307-1963 (International) and give the participant pass code 6082771. To access the live and replay webcast, please

visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.

About

Stereotaxis

(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission

is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory.

These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive

therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to

treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

This

press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”,

“estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve

risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences

include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s

products in the marketplace, the effect of global economic conditions, including tariffs, on the ability and willingness of customers

to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing

of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisitions, including any benefits

expected from the acquisitions, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange

Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions

or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase

orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside

of the Company’s control and may be revised, modified, delayed, or canceled.

Company

Contacts:

David

L. Fischel

Chairman

and Chief Executive Officer

Kimberly

R. Peery

Chief

Financial Officer

314-678-6100

Investors@Stereotaxis.com

Stereotaxis,

Inc.

CONSOLIDATED

STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except share and per share amounts)

Three Months Ended

March 31,

2026

2025

Revenue:

Systems

$ 1,319

$ 1,964

Disposables, service and accessories

4,972

5,508

Total revenue

6,291

7,472

Cost of revenue:

Systems

804

1,667

Disposables, service and accessories

1,693

1,741

Total cost of revenue

2,497

3,408

Gross margin

3,794

4,064

Operating expenses:

Research and development

2,397

2,350

Sales and marketing

2,617

3,148

General and administrative

4,761

4,495

Total operating expenses

9,775

9,993

Operating loss

(5,981 )

(5,929 )

Other income

(5 )

Interest income, net

125

106

Net loss

$ (5,861 )

$ (5,823 )

Cumulative dividend on convertible preferred stock

(311 )

(314 )

Net loss attributable to common stockholders

$ (6,172 )

$ (6,137 )

Net loss per share attributed to common stockholders:

Basic

$ (0.06 )

$ (0.07 )

Diluted

$ (0.06 )

$ (0.07 )

Weighted average number of common shares and equivalents:

Basic

98,891,179

87,769,366

Diluted

98,891,179

87,769,366

STEREOTAXIS,

INC.

CONSOLIDATED

BALANCE SHEETS

(in thousands, except share amounts)

March 31,

2026

December 31,

2025

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$ 14,616

$ 13,421

Accounts receivable, net of allowance of $630 and $541 at 2026 and 2025, respectively

5,303

5,847

Insurance receivable

4,316

Inventories, net

10,495

9,567

Prepaid expenses and other current assets

1,297

698

Total current assets

36,027

33,849

Property and equipment, net

2,956

3,019

Goodwill

3,764

Intangible assets, net

6,193

6,429

Operating lease right-of-use assets

4,760

4,912

Prepaid and other non-current assets

330

278

Total assets

$ 54,030

$ 52,251

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$ 4,823

$ 4,768

Accrued liabilities

1,478

2,065

Accrued legal liabilities

4,316

Deferred revenue

6,541

5,675

Current contingent consideration

5,266

4,894

Current portion of operating lease liabilities

662

642

Total current liabilities

23,086

22,360

Long-term deferred revenue

523

555

Long-term contingent consideration

5,108

4,724

Operating lease liabilities

4,618

4,794

Other liabilities

1,097

Total liabilities

34,432

33,530

Series A - Convertible preferred stock:

Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 21,008 shares outstanding at 2026 and 2025

5,240

Stockholders’ equity:

Common stock, par value $0.001; 300,000,000 shares authorized, 97,491,248 and 95,339,628 shares issued at 2026 and 2025, respectively

Additional paid-in capital

603,696

596,960

Treasury stock, 4,015 shares at 2026 and 2025

(206 )

Accumulated deficit

(589,229 )

(583,368 )

Total stockholders’ equity

14,358

13,481

Total liabilities and stockholders’ equity

$ 54,030

$ 52,251

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (4242 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 19

v3.26.1

Cover

May 12, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 12, 2026

Entity File Number

001-36159

Entity Registrant Name

STEREOTAXIS,

INC.

Entity Central Index Key

0001289340

Entity Tax Identification Number

94-3120386

Entity Incorporation, State or Country Code

Entity Address, Address Line One

710

North Tucker Boulevard

Entity Address, Address Line Two

Suite 110

Entity Address, City or Town

St. Louis

Entity Address, State or Province

Entity Address, Postal Zip Code

63101

City Area Code

(314)

Local Phone Number

678-6100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

STXS

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration